1. Multicore iron oxide nanoparticles for magnetic hyperthermia and combination therapy against cancer cells.
- Author
-
García-Soriano D, Milán-Rois P, Lafuente-Gómez N, Rodríguez-Díaz C, Navío C, Somoza Á, and Salas G
- Subjects
- Humans, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Cell Survival drug effects, MicroRNAs metabolism, MicroRNAs genetics, Cell Line, Tumor, Particle Size, Drug Screening Assays, Antitumor, Combined Modality Therapy, Surface Properties, Cell Proliferation drug effects, Hyperthermia, Induced, Magnetic Iron Oxide Nanoparticles chemistry
- Abstract
Hypothesis: Multicore flower-like iron oxide nanoparticles (IONPs) are among the best candidates for magnetic hyperthermia applications against cancers. However, they are rarely investigated in physiological environments and their efficacy against cancer cells has been even less studied. The combination of magnetic hyperthermia, using multicore IONPs, with selected bioactive molecules should lead to an enhanced activity against cancer cells., Experiments: Multicore IONPs were synthesized by a seeded-growth thermal decomposition approach. Then, the cytotoxicity, cell uptake, and efficacy of the magnetic hyperthermia approach were studied with six cancer cell lines: PANC1 (pancreatic carcinoma), Mel202 (uveal melanoma), MCF7 (breast adenocarcinoma), MB231 (triple-negative breast cancer line), A549 (lung cancer), and HCT116 (colon cancer). Finally, IONPs were modified with a chemotherapeutic drug (SN38) and tumor suppressor microRNAs (miR-34a, miR-182, let-7b, and miR-137), to study their activity against cancer cells with and without combination with magnetic hyperthermia., Findings: Two types of multicore IONPs with very good heating abilities under magnetic stimulation have been prepared. Their concentration-dependent cytotoxicity and internalization have been established, showing a strong dependence on the cell line and the nanoparticle type. Magnetic hyperthermia causes significant cell death that is dramatically enhanced in combination with the bioactive molecules., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF